# OnCo record emergent-biosolutions (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/emergent-biosolutions/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "emergent-biosolutions" ;
  schema:name "Emergent BioSolutions"@en ;
  schema:alternateName "Emergent BioSolutions Inc."@en, "Trubion Pharmaceuticals"@en ;
  schema:description "Emergent is a Maryland vaccines and biodefence company whose brief oncology venture, the anti-CD37 protein otlertuzumab inherited from Trubion, reached late trials in chronic lymphocytic leukaemia before being shelved."@en ;
  schema:url <https://onco.cc/companies/emergent-biosolutions/>, <https://www.emergentbiosolutions.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Emergent_BioSolutions> ;
  owl:sameAs <http://www.wikidata.org/entity/Q5370757> ;
  schema:citation <https://www.emergentbiosolutions.com>, <https://clinicaltrials.gov/search?lead=Emergent%20BioSolutions%20Inc.>, <https://www.wikidata.org/wiki/Q5370757> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:terms <https://onco.cc/terms/pivotal-trial/>, <https://onco.cc/terms/clinical-trial/> .